Italia markets closed

Novartis AG (NOVN.SW)

Swiss - Swiss Prezzo differito. Valuta in CHF.
Aggiungi a portafoglio
73,57-0,23 (-0,31%)
Alla chiusura: 05:30PM CET

Novartis AG

Lichtstrasse 35
Basel 4056
41 61 324 1111

SettoreDrug Manufacturers—General
Impiegati a tempo pieno108.000

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Vasant NarasimhanChief Exec. Officer4,67MN/D1976
Mr. Harry KirschChief Financial Officer2,46MN/D1965
Mr. Steffen Lang Ph.D.Global Head of Technical Operations1,85MN/D1967
Dr. Klaus Moosmayer Ph.D.Chief Ethics, Risk & Compliance Officer1,22MN/D1968
Dr. John TsaiHead of Global Drug Devel. & Chief Medical Officer2,11MN/D1967
Mr. Robert WeltevredenHead of Customer & Technology Solutions1,44MN/D1969
Ms. Susanne Schaffert Ph.D.Pres of Novartis Oncology2,76MN/D1967
Mr. Richard SaynorChief Exec. Officer of Sandoz3,49MN/D1967
Dr. James E. Bradner M.D.Pres of Novartis Institutes for Biomedical Research3,2MN/D1972
Ms. Marie-France TschudinPres of Novartis Pharmaceuticals1,93MN/D1971
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.


Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Novartis AG al 26 settembre 2021 è 2. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 2; diritti degli azionisti: 9; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.